Entrada Therapeutics, Inc. (TRDA) Cash Flow Statement
Entrada Therapeutics, Inc. (TRDA) generated -$134.7M of operating cash flow over the twelve months to 2026-06-30, spent -$323000 on capital expenditure and had free cash flow of -$134.4M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TRDAEntrada Therapeutics, Inc.Follow TRDA — free
—
Price chart with a free account
- Market cap
- 171.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | 139.8 | -41.6 | -128.5 | -134.7 | |
| Capital expenditure | 5.6 | 3.2 | 1.0 | 0.3 | |
| Free cash flow | 134.2 | -44.7 | -129.6 | -134.4 | |
| Stock-based compensation | 13.1 | 17.9 | 19.6 | — |
USD millions · SEC XBRL
Entrada Therapeutics, Inc. — questions
- What is Entrada Therapeutics, Inc.'s operating cash flow?
- -$134.7M over the twelve months to 2026-06-30.
- How much does Entrada Therapeutics, Inc. spend on capital expenditure?
- -$323000 over the twelve months to 2026-06-30.
- What is Entrada Therapeutics, Inc.'s free cash flow?
- -$134.4M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Entrada Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.